A multicenter¸open label phase II trial of liposomal doxorubicin (LD) and docetaxel (DX), followed by concurrent chemotherapy and radiation therapy in locally advanced high risk, early breast cancer (HRBC). A multicenter¸open label phase II trial of liposomal doxorubicin (LD) and docetaxel (DX), followed by concurrent chemotherapy and radiation therapy in locally advanced high risk, early breast cancer (HRBC). J Clin Oncol 30: 2012 (ASCO MEETING ABSTRACTS May 30, 2012:e11041 ASCO MEETING ABSTRACTS May 30, 2012:e11041

DESIDERI, GIOVAMBATTISTA;Necozione S;REA, Silvio
2012-01-01

File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11697/22520
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact